The Sweet Spot: Heart Failure Prevention with SGLT2 inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of medications that reduce plasma glucose concentrations through an insulin-independent mechanism of increased urinary glucose excretion, with concomitant natriuresis and diuresis. Clinical outcomes trials with SGLT2 inhibitors revealed a cardioprotective benefit among patients with diabetes mellitus, with a consistent reduction in hospitalization for heart failure. As such, the 2018 updated US and European treatment guidelines for diabetes mellitus incorporated SGLT2 inhibitors as second line glucose lowering agents after metformin.
Source: The American Journal of Medicine - Category: General Medicine Authors: Orly Vardeny Tags: Review Source Type: research
More News: Cardiology | Diabetes | Diabetes Mellitus | Endocrinology | Fortamet | General Medicine | Heart | Heart Failure | Insulin | Metformin | SGLT2 Inhibitors | Sodium